Home' Australian Pharmacist : Australian Pharmacist November 2015 Contents Australian Pharmacist November 2015 I ©Pharmaceutical Society of Australia Ltd.
The gene therapy pipeline has 906 products in active development across
However, the majority of these remain in
early stages of development, with 76%
at either the Discovery or Preclinical
stage, according to business intelligence
provider GBI Research.
The company's report, Gene Therapy:
A Diverse Range of Technologies with a
Promising Long-Term Outlook, states that
oncology, infectious diseases, genetic
disorders, cardiovascular diseases and
ophthalmological indications are the
most active pipeline sectors, as well as
the most widely studied in terms of the
number of clinical trials.
There are 266 pipeline gene therapies
in active development for oncology,
more than double that of central
nervous system disorders, which is
the second-largest therapy area.
Furthermore, oncology also accounted
for 64% of gene therapy clinical trials
between 1989 and 2012.
Dominic Trewartha, Managing Analyst
for GBI Research, said: 'Oncology
is the predominant area for gene
therapy developments due to its high
prevalence and genetically driven
'One reason for the large overall pipeline
is the potential for these therapies to
develop strong drugs by targeting
diseases on a genetic level. Although no
products have yet fulfilled this promise,
developers expect this in the future.'
The report also states that, based on
pipeline activity, Isis Pharmaceuticals
is a major player in the gene therapy
research and development space,
with 31 gene silencing-based programs
in development across the key
therapy areas. Sarepta and Alnylam
Pharmaceuticals are also key players,
with 25 and 24 pipeline products in
Mr Trewartha said: 'In the next decade,
these late-stage pipeline developments
may translate into clinically and
commercially successful gene therapies
entering the market. However, high
pipeline failure rates due to challenges
in developing safe and efficient delivery
vectors will remain a barrier.
'Other potential obstacles to gene
therapy development include difficulties
in manufacturing and purifying viral
vectors, as well as increased regulatory
oversight by the US Food and Drug
Administration and general caution
from worldwide regulatory bodies
following previous trial deaths.'
New NPSA president
Sigma Pharmaceuticals CEO Mark Hooper
was been elected President of the National
Pharmaceutical Services Association
(NPSA) last month.
He replaces EBOS CEO Patrick Davies who
has served in the role twice, most recently
'On behalf of the NPSA members, I'd like
to thank Patrick for his tireless efforts in
leading the NPSA through what has been
a very challenging time for the industry.
His guidance has been instrumental as we
worked together to strengthen the supply
chain to ensure a sustainable platform for
the services provided by wholesalers to
both community pharmacy and patients,'
Mr Hooper said.
'The upcoming review of pharmacy
regulation and remuneration is the next
milestone for the NPSA, and we look
forward to being an important part of that
process.' Mr Davies will continue to sit on
the NPSA Board.
MA Chairman retires
Medicines Australia (MA) Chairman,
Dr Martin Cross retired from the MA Board
on 20 October.
Dr Cross was appointed to the MA
Board and made Chairman in 2013
after almost 30 years in the global
During his time as Chairman MA
re-launched the Access to Medicines
Working Group which is finalising new
frameworks for the Managed Access
Programme and Post Marketing Reviews
and meeting regularly to progress PBS
Other achievements include:
• Recognition by government of the
sector is one of five identified in its
Innovation and Competitiveness
Agenda and the development of an
Industry Growth Centre
• Extensive consultation, authorisation
and implementation of the 18th Edition
of the MA Code of Conduct which
includes sector-leading transparency
in gene therapy
Links Archive Australian Pharmacist October 2015 Australian Pharmacist December 2015 Navigation Previous Page Next Page